NCT02622074View on ClinicalTrials.gov

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 27, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

November 18, 2019

Conditions
Triple Negative Breast Neoplasms
Interventions
BIOLOGICAL

Pembrolizumab

200 mg administered Q3W as an IV infusion.

DRUG

Nab-paclitaxel

125 mg/m\^2 or 100 mg/m\^2 administered weekly as an IV infusion, according to allocation.

DRUG

Anthracycline (doxorubicin)

60 mg/m\^2 administered Q3W as an IV injection.

DRUG

Cyclophosphamide

600 mg/m\^2 administered Q3W as an IV infusion.

DRUG

Carboplatin

AUC 6 or AUC5 administered Q3W as an IV infusion, or AUC2 administered weekly as an IV infusion, according to allocation.

DRUG

Paclitaxel

80 mg/m\^2 or 70 mg/m\^2 administered weekly as an IV infusion, according to allocation.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02622074 - Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | Biotech Hunter | Biotech Hunter